Evaluation of Protein in the Urine in Patients Receiving Bevacizumab

An Evaluation of Proteinuria in Patients Receiving Shortened Infusions of Bevacizumab

This is a clinical research study to look at the incidence of proteinuria (a condition in which urine contains an abnormal amount of protein) caused by shortened infusions (given into the vein over 10 or 15 minutes) of bevacizumab (a medication prescribed for colon, lung, or breast cancer). There are currently no published studies or clinical data looking at how safe shortened infusions of bevacizumab are in relationship to the side effect of proteinuria. We hypothesis that shortened infusions of bevacizumab will result in an increased risk for proteinuria compared to the standard infusions of this agent.

Inclusion Criteria:

• Patients must be 18 years older
• Patients must be receiving his/her first dose of bevacizumab
• Patients must sign an informed consent

Exclusion Criteria:

• Patients receiving > 10 mg/kg doses of bevacizumab